A data analysis found the inhaled therapy Tyvaso outperformed a placebo at preserving lung function in people with IPF in a ...

Reinventing pulmonary care medically improves early diagnosis and interdisciplinary management for complex patients with COPD and co-morbidities.

A pulmonologist discusses the history and influence of race-based reference equations in pulmonary function testing interpretation and patient care.

February 2026 coverage highlighted combination EGFR therapy guidance, chemo-free treatment options, biomarker testing and ...

bSchool of Nursing, Hunan University of Medicine, Huaihua, Hunan Province, China cSchool of Nursing, Zunyi Medical University, Zunyi, Guizhou Province, China dThoracic Surgery Department, Affiliated ...

NEW YORK — BioAffinity Technologies said on Wednesday that it will run a study of its CyPath Lung test for early lung cancer detection in collaboration with Brooke Army Medical Center (BAMC). CyPath ...

SAN ANTONIO, February 25, 2026--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today ...

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrotic interstitial lung disease of unknown cause. Its main feature is a steady decline in lung function, which is also the primary ...

Lung adenocarcinoma (LUAD), the most common subtype of non-small cell lung cancer, is a form of malignant pulmonary nodule that requires clinical differentiation from benign pulmonary nodules (BPN).

Pulmonary function is linked to cardiovascular disease risk; however, the underlying mechanisms remain unclear. We aimed to identify protein biomarkers associated with pulmonary function and examine ...

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW),a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced a new clinical case study ...